Compare Abeona Therapeutics Inc (ABEO) vs Nucor Corporation (NUE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nucor Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Nucor Corporation trades at $225.48 (market cap $51.79B). The key difference: Nucor Corporation is far larger — about 138.7× Abeona Therapeutics Inc's market cap, and Nucor Corporation pays a 0.98% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NUE | |
|---|---|---|
Market Cap | $373.32M | $51.79B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $266.35 |
52-Week Low | $4.17 | $131.78 |
Enterprise Value | $228.22M | $56.44B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Nucor (NUE) trades at $227.42, up 3.02% over the past day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with 59% analyst buy ratings but faces declining revenue and net income from 2022 peaks. Recent developments include a joint venture to support AI power infrastructure and a consistent dividend history, with Q2 2026 EPS guidance projecting growth.
Outlook remains cautiously optimistic due to strong analyst targets averaging $260.75 and operational expansions, though risks include steel demand volatility and compressed profit margins. The stock's valuation at a P/E of 22.21 appears reasonable if earnings rebound as projected in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
